Toxins 2010, 2(5), 998-1018; doi:10.3390/toxins2050998
Review

Toxin-Specific Antibodies for the Treatment of Clostridium difficile: Current Status and Future Perspectives

email and * email
Received: 26 March 2010; in revised form: 29 April 2010 / Accepted: 5 May 2010 / Published: 7 May 2010
(This article belongs to the Special Issue Enterotoxins)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Therapeutic agents targeting bacterial virulence factors are gaining interest as non-antibiotic alternatives for the treatment of infectious diseases. Clostridium difficile is a Gram-positive pathogen that produces two primary virulence factors, enterotoxins A and B (TcdA and TcdB), which are responsible for Clostridium difficile-associated disease (CDAD) and are targets for CDAD therapy. Antibodies specific for TcdA and TcdB have been shown to effectively treat CDAD and prevent disease relapse in animal models and in humans. This review summarizes the various toxin-specific antibody formats and strategies under development, and discusses future directions for CDAD immunotherapy, including the use of engineered antibody fragments with robust biophysical properties for systemic and oral delivery.
Keywords: Clostridium difficile; Clostridium difficile-associated disease; toxin; antibody; single-domain antibody; neutralization; therapy
PDF Full-text Download PDF Full-Text [279 KB, uploaded 7 May 2010 09:11 CEST]

Export to BibTeX |
EndNote


MDPI and ACS Style

Hussack, G.; Tanha, J. Toxin-Specific Antibodies for the Treatment of Clostridium difficile: Current Status and Future Perspectives. Toxins 2010, 2, 998-1018.

AMA Style

Hussack G, Tanha J. Toxin-Specific Antibodies for the Treatment of Clostridium difficile: Current Status and Future Perspectives. Toxins. 2010; 2(5):998-1018.

Chicago/Turabian Style

Hussack, Greg; Tanha, Jamshid. 2010. "Toxin-Specific Antibodies for the Treatment of Clostridium difficile: Current Status and Future Perspectives." Toxins 2, no. 5: 998-1018.


Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert